TruePrime© DNA amplification
- Suitable for small and large constructs (0.1 – 20kb)
- High fidelity
- High processivity
- No sequence context bias
- No primer artefacts
4basebio’s TruePrime© DNA amplification technology is a primer free DNA amplification method using proprietary enzymes with high fidelity and processivity resulting in fast and accurate copying of the DNA strands. This enables 4basebio to cost effectively produce large quantities of high-quality genes.
4basebio’s TruePrime© can work of any DNA starting material including:
- Purified DNA: Plasmids, cosmids, BACs, M13 clones, etc
- Bacterial cells transformed with plasmids: colonies picked from agar plates, bacterial cultures or glycerol stocks
- No bacterial backbone
- No antibiotic resistance genes
- No bacterial contaminants (host protein, genomic DNA, endotoxins, …)
- Enhanced in vivo stability
- Better and prolonged transgene expression
hpDNATM is a linear form of double stranded DNA with both ends closed with hairpin loops to enhance the stability of the DNA and protect it from enzymatic breakdown. hpDNATM is made using Trueprime technology ensuring the highest accuracy in the manufacture of the product.
Unlike plasmid DNA, hpDNATM does not contain a bacterial backbone which results in a higher amount of genome copies of interest per gram of DNA; this can substantially enhance transgene expression. Furthermore, as the DNA is manufactured entirely synthetically, it does not contain any of the toxic bacterial contaminants that are inherently present in the production of plasmid DNA and is therefore a safe and cost-effective alternative to plasmid DNA.
hpDNATM gene production
4basebio can produce hpDNATM for any gene of interest. We can assist with the construct design, promoter selection and codon optimisation and produce the quantities required for your research or product development program.
Depending on the stage of product development different grades of DNA are required. 4basebio offers competitive and fast turnaround on research grade hpDNATM which can be used in a variety of discovery and pre-clinical applications. We are working on GMP grade DNA becoming available in 2021 suitable for use in clinical trials.
We produce research grade hpDNATM for a variety of research and pre-clinical applications.
Our research-grade production facilities provide the flexibility needed to offer competitive pricing and rapid turnaround times while still maintaining the quality our clients expect.
HermesTM non-viral delivery
- Suitable for protein, RNA and DNA
- Suitable for small and large nucleotide payload (unlimited packaging capacity)
- Non-immunogenic, repeat dosing possible
- Low toxicity
- Ability to target specific cells or tissues
- Excellent transfection capabilities
- Enhanced payload delivery to cytoplasm and nucleus
- Excellent safety profile as compared to viral delivery (low risk of insertional mutagenesis)
- Low cost of production as compared to viral vectors
- Simple manufacturing process
HermesTM is a non-viral delivery platform that can be used to deliver various payloads, ranging from DNA to siRNA, as well as protein cargoes. HermesTM nanoparticles can be engineered to target particular cells and tissues, enhancing their specificity whilst minimising off-target effects. Once taken into the target cell, the particles are designed to efficiently release their payload. The particles self-assemble into small, discrete units with favourable biophysical characteristics for scalability and clinical translation. Unlike viral delivery mechanisms, HermesTM nanoparticles are non-immunogenic, allowing repeat dosing with lower associated safety risks. HermesTM nanoparticles have a vast packaging capacity and hence are ideally suited for larger genes and payloads which cannot be delivered with adeno associated viral vectors.
- Multiplexed in vivo analysis of different DNA constructs and or NP formulations
- Avoid in vitro – in vivo correlation disparity
- Fast biodistribution and toxicity assessment
To circumvent the often-poor correlation between in vitro and in vivo data sets our approach is to move to in vivo validation sooner rather than later. Incorporation of DNA barcodes directly into our hpDNATM payloads allows for simultaneous screening of a variety of molecular biology elements within the payloads as well as different elements used in the construction of the nanoparticles. This approach not only speeds up the development of the vectors but also enables early selection of candidates with the strongest in vivo performance for deployment into clinical trials.